Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 5
2009 1
2010 4
2011 4
2012 4
2013 3
2014 1
2015 3
2016 4
2017 7
2018 3
2019 5
2020 4
2021 1
2022 6
2023 5
2024 6
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Panaccione R, et al. Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17. Lancet. 2025. PMID: 40684778 Clinical Trial.
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M; EXIT Study group of GETECCU. Gisbert JP, et al. Among authors: van domselaar m. Gut. 2025 Feb 6;74(3):387-396. doi: 10.1136/gutjnl-2024-333385. Gut. 2025. PMID: 39794921 Free PMC article. Clinical Trial.
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, Gisbert JP; ULISES study group. Chaparro M, et al. Among authors: van domselaar m. Aliment Pharmacol Ther. 2024 Nov;60(10):1325-1338. doi: 10.1111/apt.18230. Epub 2024 Sep 17. Aliment Pharmacol Ther. 2024. PMID: 39287363
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA.
Gargallo-Puyuelo CJ, Ricart E, Iglesias E, de Francisco R, Gisbert JP, Taxonera C, Mañosa M, Aguas Peris M, Navarrete-Muñoz EM, Sanahuja A, Guardiola J, Mesonero F, Rivero Tirado M, Barrio J, Vera Mendoza I, de Castro Parga L, García-Planella E, Calvet X, Martín Arranz MD, García S, Sicilia B, Carpio D, Domenech E, Gomollón F; ENEIDA registry of GETECCU. Gargallo-Puyuelo CJ, et al. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2280-2290. doi: 10.1016/j.cgh.2024.05.013. Epub 2024 May 22. Clin Gastroenterol Hepatol. 2024. PMID: 38782172
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry.
Palomino L, Velasco Rodríguez-Belvís M, Casanova MJ, Leo-Carnerero E, Calviño-Suárez C, Rivero M, Calvo M, Arroyo MT, Fernández-Clotet A, Pérez-Martínez I, Masedo González Á, Hernández V, Ruiz-Cerulla A, López Serrano P, Vega P, Rodríguez-Lago I, Lidón RV, De Jorge MÁ, Guerra I, García LA, Molina Arriero G, Hervías Cruz D, Busquets D, Gutiérrez Casbas A, Van Domselaar M, Valldosera Gomis G, Vázquez Morón JM, Piqueras Cano M, Lucendo AJ, Martín Arranz MD, Ramírez de la Piscina P, Martínez Tirado MDP, Robles Alonso V, Marín Pedrosa S, Camargo Camero R, Armesto Gonzalez E, Tardillo Marín C, Bernardos Martín E, Rodríguez Grau MC, Huguet JM, Márquez-Mosquera L, Sendra Rumbeu P, Bujanda L, Castaño-Milla C, Sáinz Arnau E, Hernández L, Ramos L, Boscá-Watts MM, Manceñido Marcos N, Sans M, Morales VJ, Acosta D, Garre A, Muñoz Codoceo R, García-Salido A, Gisbert JP, Chaparro M; DUMBO study group of GETECCU. Palomino L, et al. Among authors: van domselaar m. Clin Gastroenterol Hepatol. 2025 Jun 13:S1542-3565(25)00488-4. doi: 10.1016/j.cgh.2025.05.012. Online ahead of print. Clin Gastroenterol Hepatol. 2025. PMID: 40518059 Free article.
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.
Rubín de Célix C, Ricart E, Martín-Arranz MD, de Francisco R, García-Alonso FJ, Mesonero F, Gomollón F, de Castro L, Ramos L, García-López S, Arias L, Mañosa M, Iglesias E, Calvet X, Suria Bolufer C, Casanova MJ, Pérez-Calle JL, Giordano A, Sierra-Ausín M, Vera I, Navarro-Llavat M, Lorente R, Piqueras M, Rivero M, Guardiola J, Esteve M, Fuentes Coronel A, Rodríguez-Lago I, Ponferrada-Díaz Á, Ber Y, Tardillo C, Márquez L, Carpio D, Taxonera C, Bermejo F, Busquets D, Camps B, Gutiérrez A, García-Sepulcre MF, Barreiro-de Acosta M, Marín-Jiménez I, Huguet JM, Fernández-Salazar LI, Jaó J, Rodríguez-Gutiérrez C, Martínez-Flores C, Bujanda L, Lucendo AJ, Sesé E, Robledo Andrés P, Ginard D, Vega P, Riera J, Pajares R, Van Domselaar M, Almela P, Martínez Pérez T, Muñoz-Villafranca C, Varela P, Argüelles-Arias F, Nos P, Alcaín G, Hernández L, Fernández H, Muñoz F, Gilabert P, Navas-López VM, Ramírez de la Piscina P, Buendía Sánchez L, Legido Gil J, Valldosera G, Muñoz RA, Frago S, Domènech E, Chaparro M, Gisbert JP. Rubín de Célix C, et al. Among authors: van domselaar m. Aliment Pharmacol Ther. 2025 Aug 8. doi: 10.1111/apt.70312. Online ahead of print. Aliment Pharmacol Ther. 2025. PMID: 40778752
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
Casanova MJ, Rubín de Célix C, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo-Carnerero E, Nantes-Castillejo O, Navarro P, Van Domselaar M, Gutiérrez-Casbas A, Alonso-Abreu I, Barreiro-de Acosta M, Fernández-Salazar L, Iborra M, Martín-Arranz MD, García-Morales N, Guardiola J, Bouhmidi-Assakali A, Esteve M, Muñoz-Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín-Jiménez I, Vera-Mendoza I, Garre A, Chaparro M, Gisbert JP; EXIT long‐term study group of GETECCU. Casanova MJ, et al. Among authors: van domselaar m. Aliment Pharmacol Ther. 2025 Jul;62(1):59-71. doi: 10.1111/apt.70172. Epub 2025 May 2. Aliment Pharmacol Ther. 2025. PMID: 40317957 Clinical Trial.
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias R, Porto Silva S, Marín S, Casanova MJ, Mañosa M, González-Muñoza C, de Francisco R, Caballol B, Arias L, Piqueras M, Zabana Y, Rivero M, Calvet X, Mesonero F, Varela Trastoy P, Busta Nistal R, Gómez Perosanz R, Vega P, Gonzalez-Vivo M, Iborra M, Bermejo F, Madero L, Rodríguez-Lago I, Rodríguez Gonzalez M, Vera I, Ponferrada Díaz Á, Vela M, Torrealba Medina L, Van Domselaar M, Gomollón F, Iglesias E, Gisbert JP, Calafat M, Giordano A, Pérez-Martínez I, Ricart E, Sicilia B, Mena R, Esteve M, Rivas C, Brunet-Mas E, Fernández C, de Jorge Turrión MÁ, Velayos Jiménez B, Quiñones Calvo M, Regueiro Expósito C, Márquez-Mosquera L, Nos P, Granja A, Gutiérrez A, Cabriada JL, Hervías Cruz D, Calvo M, Pérez Pérez J, Rodríguez Díaz Y, Busquets Casal D, Menacho M, Leal C, Lucendo AJ, Royo V, Olivares S, Álvarez Herrero B, Carrillo-Palau M, Gilabert Álvarez P, Manceñido Marcos N, Martínez-Pérez TJ, Muñoz Villafranca MC, Almela P, Argüelles-Arias F, Legido J, Fuentes Coronel AM, Nieto L, Domènech E, Barreiro-de Acosta M; ENEIDA project sponsored by GETECCU. Ferreiro-Iglesias R, et al. Among authors: van domselaar m. Aliment Pharmacol Ther. 2024 Sep;60(5):604-612. doi: 10.1111/apt.18133. Epub 2024 Jun 28. Aliment Pharmacol Ther. 2024. PMID: 38943230
[Adalimumab in Crohn's disease - data from real life].
López San Román A, Van Domselaar M, Garrido E. López San Román A, et al. Among authors: van domselaar m. Rev Esp Enferm Dig. 2008 Nov;100(11):671-5. doi: 10.4321/s1130-01082008001100001. Rev Esp Enferm Dig. 2008. PMID: 19159169 Free article. Spanish. No abstract available.
61 results